Services on Demand
Journal
Article
Indicators
- Cited by SciELO
Related links
- Similars in SciELO
Share
Revista argentina de endocrinología y metabolismo
On-line version ISSN 1851-3034
Abstract
BONNEAU, G. A. et al. IDL-cholesterol and lipidic parameters in diabetic patients type 2. Rev. argent. endocrinol. metab. [online]. 2007, vol.44, n.4, pp.215-222. ISSN 1851-3034.
Diabetes Mellitus is in the sixth death cause in the province of Misiones. Majority of patients die in relation with atherosclerosis, being dislipidemias one of the mechanism that explain this increased risk. We aimed to establish if there are significant differences for total cholesterol (TC), triglyceride (TG), HDL-cholesterol (HDLC), LDL-Cholesterol (LDLC), IDL-Cholesterol (IDLC), no-HDL Cholesterol and the index TC/HDLC and TG/HDLC between diabetic patients type 2 and a control group, as well as comparing the IDLC amount between both groups according to the dislipidemia phenotype. We studied 70 diabetic patients type 2 and 57 controls, with similar distribution in age, sex and body mass index. TC, TG, HDLC and LDLC were tested by enzymatic colorimetric methods with internal and external quality controls and the IDLC by Wikinski method. The results obtained in diabetic patients vs controls were (table N°1): TC 214 ±49 vs 205± 34 mg/dl (p=0.488); TG 194±119 vs 128±65 mg/dl (p<0.001); HDLC 43±11 vs 50±13 mg/dl(p=0.001); LDLC 135±43 vs 132± 32 mg/dl (p=0.934); IDLC 13.8± 8.7 vs 7.2±3.5 mg/dl (p<0.001) (figure N°1); TC/HDLC 5.26 ±1.54 vs 4.40± 1.33 (p=0.001); TG/HDLC 5.01±3.95 vs 2.97±2.24 (p<0.001) y no-HDL cholesterol 172±48 vs 155±35 mg/dl (p=0.07); at a same electrophoretic pattern ( normolipemic (p=0.043), phenotype II (p=0.006) or phenotype IV (p=0.001)),the IDLC was higher in the first group (figure N°2). The diabetic patients show a more atherogenic lipoprotein profile than the control group. The quantification of IDLC improvement the assessment of atherogenic risk in type 2 diabetic patients, specially normolipemics.
Keywords : Diabetes type 2; Lipoproteins; IDL-Cholesterol; Atherogenic risk.